Dr Reddy Laboratories
-
{
- All
- News
- Videos
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Cyber Fraud Targeting Drugmaker Dr Reddy's Busted, Rs 2.16 Crore Recovered
Group Pharmaceuticals was due to receive a payment of Rs 2.16 crore from Dr. Reddy's Laboratories. However, hackers gained access to their emails and diverted funds.
-
How Hackers Duped Drugmakers Dr Reddy's, Group Pharmaceuticals Of Rs 2 Crore
In a major case of cyber fraud, a sum of Rs 2.16 crore has been siphoned off after fraudsters hacked email communications between Bengaluru-based Group Pharmaceuticals Ltd and Dr. Reddy's Laboratories in Hyderabad
-
Dr Reddy's Laboratories Gets FDA Approval, Launches Drug In US Market
Dr Reddy's Laboratories on Wednesday said it has launched a vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
-
Proposal For Sputnik Light As Covid Booster Submitted To Drug Regulator
Drug major Dr Reddy's Laboratories has submitted a proposal to the Drugs Controller General of India (DCGI) to register Sputnik Light vaccine as a booster dose against COVID-19, a top company official has said.
-
Trying To Bring Vaccine For 12-18 Age Group To India: Dr Reddy's
Dr Reddy's Laboratories on Friday said it is in discussions with the Indian drug regulator to bring Russia's Sputnik M, a COVID-19 vaccine for the 12 to18-year-old category, to India.
-
Merck's Anti- Covid Pill 'Molflu' 5-Day Course To Cost Rs 1,400 In India
Drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir.
-
Why Top Drugmaker Is Surprisingly Downbeat About Covid Pill, Sputnik Shot
For a drugmaker licensed to produce Merck & Co.'s promising Covid-19 pill and sell Russia's Sputnik V shot, Dr Reddy's Laboratories Ltd. is surprisingly mellow about the rewards it expects from these medical breakthroughs.
-
Dr Reddy's Open To Making Pfizer Covid Pill
Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
-
Dr Reddy's Hopes To Submit Sputnik V Light Trial Data To Drug Regulator In November
Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18
-
Health Minister Meets Top Vaccine Bosses, Takes Stock Of Production Status
Union Health Minister Mansukh Mandaviya on Friday held separate meetings with Serum Institute of India CEO Adar Poonawalla and Biological-E MD Mahima Dalta to discuss issues regarding COVID-19 vaccines.
-
Dr Reddy's Says Made-In-India Sputnik V Doses To Be Available From September-October
Dr Reddy's Laboratories Ltd expects the locally manufactured Russia's COVID-19 vaccine Sputnik V to be available from September-October period, a senior official of the city-based drug maker said on Tuesday.
-
Dr Reddy's Assures Strengthening Roll-Out Of Sputnik V In Coming Weeks
Dr Reddy's Laboratories on Monday assured to "strengthen" the commercial roll-out of Sputnik V vaccines in the coming weeks.
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
Dr Reddy's Announces Commercial Launch Of Covid Drug 2-DG, Caps Price
Dr Reddy's Laboratories today announced the commercial launch of 2-Deoxy-D-Glucose (2-DG) used to treat Covid patients, adding that the drug will be available across hospitals in metros and Tier 1 cities in the initial weeks.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Cyber Fraud Targeting Drugmaker Dr Reddy's Busted, Rs 2.16 Crore Recovered
Group Pharmaceuticals was due to receive a payment of Rs 2.16 crore from Dr. Reddy's Laboratories. However, hackers gained access to their emails and diverted funds.
-
How Hackers Duped Drugmakers Dr Reddy's, Group Pharmaceuticals Of Rs 2 Crore
In a major case of cyber fraud, a sum of Rs 2.16 crore has been siphoned off after fraudsters hacked email communications between Bengaluru-based Group Pharmaceuticals Ltd and Dr. Reddy's Laboratories in Hyderabad
-
Dr Reddy's Laboratories Gets FDA Approval, Launches Drug In US Market
Dr Reddy's Laboratories on Wednesday said it has launched a vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
-
Proposal For Sputnik Light As Covid Booster Submitted To Drug Regulator
Drug major Dr Reddy's Laboratories has submitted a proposal to the Drugs Controller General of India (DCGI) to register Sputnik Light vaccine as a booster dose against COVID-19, a top company official has said.
-
Trying To Bring Vaccine For 12-18 Age Group To India: Dr Reddy's
Dr Reddy's Laboratories on Friday said it is in discussions with the Indian drug regulator to bring Russia's Sputnik M, a COVID-19 vaccine for the 12 to18-year-old category, to India.
-
Merck's Anti- Covid Pill 'Molflu' 5-Day Course To Cost Rs 1,400 In India
Drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir.
-
Why Top Drugmaker Is Surprisingly Downbeat About Covid Pill, Sputnik Shot
For a drugmaker licensed to produce Merck & Co.'s promising Covid-19 pill and sell Russia's Sputnik V shot, Dr Reddy's Laboratories Ltd. is surprisingly mellow about the rewards it expects from these medical breakthroughs.
-
Dr Reddy's Open To Making Pfizer Covid Pill
Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
-
Dr Reddy's Hopes To Submit Sputnik V Light Trial Data To Drug Regulator In November
Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18
-
Health Minister Meets Top Vaccine Bosses, Takes Stock Of Production Status
Union Health Minister Mansukh Mandaviya on Friday held separate meetings with Serum Institute of India CEO Adar Poonawalla and Biological-E MD Mahima Dalta to discuss issues regarding COVID-19 vaccines.
-
Dr Reddy's Says Made-In-India Sputnik V Doses To Be Available From September-October
Dr Reddy's Laboratories Ltd expects the locally manufactured Russia's COVID-19 vaccine Sputnik V to be available from September-October period, a senior official of the city-based drug maker said on Tuesday.
-
Dr Reddy's Assures Strengthening Roll-Out Of Sputnik V In Coming Weeks
Dr Reddy's Laboratories on Monday assured to "strengthen" the commercial roll-out of Sputnik V vaccines in the coming weeks.
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
Dr Reddy's Announces Commercial Launch Of Covid Drug 2-DG, Caps Price
Dr Reddy's Laboratories today announced the commercial launch of 2-Deoxy-D-Glucose (2-DG) used to treat Covid patients, adding that the drug will be available across hospitals in metros and Tier 1 cities in the initial weeks.
